Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 3,828 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total value of $69,286.80. Following the transaction, the chief operating officer directly owned 210,164 shares of the company’s stock, valued at $3,803,968.40. This represents a 1.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total transaction of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.68, for a total transaction of $233,500.00.
• On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.05, for a total transaction of $225,625.00.

Bicara Therapeutics Trading Down 1.9%

BCAX traded down $0.32 during midday trading on Monday, reaching $16.42. The company’s stock had a trading volume of 567,617 shares, compared to its average volume of 484,589. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $19.71. The stock’s 50-day moving average is $17.45 and its 200-day moving average is $14.72. The firm has a market capitalization of $899.49 million, a price-to-earnings ratio of -7.33 and a beta of -0.79.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its holdings in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. increased its position in Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics in the fourth quarter valued at about $45,000. Finally, Larson Financial Group LLC boosted its position in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.